Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Radionuclide Imaging of Chromaffin Cell Tumors

  • Chapter
  • First Online:
Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Pheochromocytomas (PHEOs) and extra-adrenal paragangliomas (PGLs) are neural crest-derived tumors associated with the sympathetic or parasympathetic nervous systems. Successful pheochromocytoma/paraganglioma management now requires an interdisciplinary team approach. Precise identification of clinical context and the patient’s genetic status enables a personalized use of genetic and biochemical tests carefully followed by the application of genotype- and biochemical-specific functional imaging modalities. Once these tumors are identified, their patient-specific management, termed personalized medicine, is applied to achieve the best treatment outcome. This chapter particularly emphasizes the current and emerging knowledge of imaging options for chromaffin tumors tailored to their unique localization, biochemical phenotype, genetic landscape, malignant predisposition, and, ultimately, metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958–1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220(3):225–32.

    Article  CAS  PubMed  Google Scholar 

  2. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.

    CAS  PubMed  Google Scholar 

  3. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006;1073:30–7.

    Article  PubMed  Google Scholar 

  4. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665–75.

    Article  PubMed  Google Scholar 

  5. Turkova H, Prodanov T, Maly M, Martucci V, Adams K, Widimsky Jr J, et al. Characteristics and outcomes of metastatic Sdhb and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health Study. Endocr Pract. 2016;22(3):302–14.

    Article  PubMed  Google Scholar 

  6. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328–33.

    Google Scholar 

  7. Pacak K, Wimalawansa SJ. Pheochromocytoma and paraganglioma. Endocr Pract. 2015;21(4):406–12.

    Article  PubMed  Google Scholar 

  8. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med. 2000;30(6):648–52.

    Article  CAS  PubMed  Google Scholar 

  9. Platts JK, Drew PJ, Harvey JN. Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond. 1995;29(4):299–306.

    CAS  PubMed  Google Scholar 

  10. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56(6):354–60.

    CAS  PubMed  Google Scholar 

  11. Schober A, Parlato R, Huber K, Kinscherf R, Hartleben B, Huber TB, et al. Cell loss and autophagy in the extra-adrenal chromaffin organ of Zuckerkandl are regulated by glucocorticoid signalling. J Neuroendocrinol. 2013;25(1):34–47.

    Article  CAS  PubMed  Google Scholar 

  12. Kohn A. Die Paraganglien. Arch Mikrosk Anat. 1903;52:262–365.

    Google Scholar 

  13. van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95(1):209–14.

    Article  PubMed  Google Scholar 

  14. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739–49.

    Article  CAS  PubMed  Google Scholar 

  15. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822–8.

    Article  CAS  PubMed  Google Scholar 

  17. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827–36.

    Article  CAS  PubMed  Google Scholar 

  18. Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler Jr JR, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35(5):795–819.

    Google Scholar 

  19. Schuttler J, Westhofen P, Kania U, Ihmsen H, Kammerecker S, Hirner A. Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery. Anasthesiol Intensivmed Notfallmed Schmerzther. 1995;30(6):341–9.

    Article  CAS  PubMed  Google Scholar 

  20. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069–79.

    Article  CAS  PubMed  Google Scholar 

  21. Lenders JW, Eisenhofer G. Pathophysiology and diagnosis of disorders of the adrenal medulla: focus on pheochromocytoma. Compr Physiol. 2014;4(2):691–713.

    Article  PubMed  Google Scholar 

  22. Luiz HV, Tanchee MJ, Pavlatou MG, Yu R, Nambuba J, Wolf K, et al. Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. Clin Endocrinol (Oxf). 2016;85(1):62–9.

    Article  Google Scholar 

  23. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735–44.

    Article  CAS  PubMed  Google Scholar 

  24. Kantorovich V, Pacak K. A new concept of unopposed beta-adrenergic overstimulation in a patient with pheochromocytoma. Ann Intern Med. 2005;142(12 Pt 1):1026–8.

    Article  PubMed  Google Scholar 

  25. Jochmanova I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst. 2013;105(17):1270–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Park BK, Kim CK, Kwon GY, Kim JH. Re-evaluation of pheochromocytomas on delayed contrast-enhanced CT: washout enhancement and other imaging features. Eur Radiol. 2007;17(11):2804–9.

    Article  PubMed  Google Scholar 

  27. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, et al. Pheochromocytoma: an imaging chameleon. Radiographics. 2004;24 Suppl 1:S87–99.

    Article  PubMed  Google Scholar 

  28. Park BK, Kim B, Ko K, Jeong SY, Kwon GY. Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: pathological correlation. Eur Radiol. 2006;16(3):642–7.

    Article  PubMed  Google Scholar 

  29. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. 2001;21(4):995–1012.

    Article  CAS  PubMed  Google Scholar 

  30. Mitchell DG. Chemical shift magnetic resonance imaging: applications in the abdomen and pelvis. Top Magn Reson Imaging. 1992;4(3):46–63.

    CAS  PubMed  Google Scholar 

  31. Varghese JC, Hahn PF, Papanicolaou N, Mayo-Smith WW, Gaa JA, Lee MJ. MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin Radiol. 1997;52(8):603–6.

    Article  CAS  PubMed  Google Scholar 

  32. Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun. 2006;27(1):31–6.

    Article  PubMed  Google Scholar 

  33. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88(9):4083–7.

    Article  CAS  PubMed  Google Scholar 

  34. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125–31.

    CAS  PubMed  Google Scholar 

  35. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50(4):513–9.

    Article  PubMed  Google Scholar 

  36. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10.

    Article  CAS  PubMed  Google Scholar 

  37. King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96(9):2779–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69(4):580–6.

    Google Scholar 

  39. Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39(8):1266–70.

    Article  CAS  PubMed  Google Scholar 

  40. Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21(17):3888–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Janssen I, Chen CC, Millo CM, Ling A, Taïeb D, Lin FI, et al. PET/CT comparing Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784–91.

    Google Scholar 

  42. Janssen I, Chen CC, Taïeb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med. 2016;57(2):186–91.

    Google Scholar 

  43. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  44. Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 1992;74(5):1082–9.

    CAS  PubMed  Google Scholar 

  45. Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56(6):847–54.

    Article  CAS  PubMed  Google Scholar 

  46. Niedermoser S, Chin J, Wangler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In vivo Evaluation of (1)(8)F-SiFAlin-modified TATE: a potential challenge for (6)(8)Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med. 2015;56(7):1100–5.

    Article  CAS  PubMed  Google Scholar 

  47. Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [(1)(1)(1)In]pentetreotide-SPECT and [(1)(8)F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf). 2011;74(1):21–9.

    Article  CAS  Google Scholar 

  48. Taïeb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39(12):1977–95.

    Google Scholar 

  49. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):1800–8.

    Article  CAS  PubMed  Google Scholar 

  51. Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):1248–57.

    Article  CAS  PubMed  Google Scholar 

  52. Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40(4):514–23.

    Article  CAS  PubMed  Google Scholar 

  53. Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518–25.

    Article  CAS  PubMed  Google Scholar 

  54. Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. J Clin Oncol. 2016;34 (suppl 4S; abstr 194).

    Google Scholar 

  55. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599–606.

    PubMed  Google Scholar 

  56. Vinik AI. Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. Endocr Pract. 2014;20(11):1222–30.

    Article  PubMed  Google Scholar 

  57. Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411–4.

    Article  CAS  PubMed  Google Scholar 

  58. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.

    Article  CAS  PubMed  Google Scholar 

  59. Imperiale A, Battini S, Averous G, Mutter D, Goichot B, Bachellier P, et al. In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. Surgery. 2016;159(4):1231–3.

    Article  PubMed  Google Scholar 

  60. Imperiale A, Moussallieh FM, Roche P, Battini S, Cicek AE, Sebag F, et al. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia. 2015;17(1):55–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Varoquaux A, le Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N, et al. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer. 2015;22(4):M1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg. 2012;397(2):155–77.

    Article  PubMed  Google Scholar 

  63. Schovanek J, Martucci V, Wesley R, Fojo T, Del Rivero J, Huynh T, et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer. 2014;14:523.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010;72(2):137–45.

    Article  CAS  Google Scholar 

  65. Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindie E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53(2):264–74.

    Google Scholar 

  66. Timmers HJ, Taïeb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):367–72.

    Google Scholar 

  67. Taïeb D, Rubello D, Al-Nahhas A, Calzada M, Marzola MC, Hindie E. Modern PET imaging for paragangliomas: relation to genetic mutations. Eur J Surg Oncol. 2011;37(8):662–8.

    Google Scholar 

  68. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37(3):484–93.

    Article  PubMed  Google Scholar 

  69. Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging. 2012;2012:324686.

    PubMed  PubMed Central  Google Scholar 

  70. Puranik AD, Kulkarni HR, Singh A, Baum RP. Peptide receptor radionuclide therapy with (90)Y/(177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). Eur J Nucl Med Mol Imaging. 2015;42(8):1223–30.

    Article  CAS  PubMed  Google Scholar 

  71. Hindie E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57(5):759–64.

    Article  PubMed  Google Scholar 

Download references

Funding

This research did not receive a specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, European Center for Research in Medical Imaging, Aix-Marseille University, 264, rue Saint-Pierre, 13385, Marseille, France

    David Taïeb MD, PhD

  2. Section on Medical Neuroendocrinology, Developmental Endocrine Oncology and Genetics Affinity Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, Room 1E-3140 10 Center Drive MSC-1109, Bethesda, MD, 20892-1109, USA

    Karel Pacak MD, PhD, DSc, FACE

Authors
  1. David Taïeb MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karel Pacak MD, PhD, DSc, FACE
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Taïeb MD, PhD .

Editor information

Editors and Affiliations

  1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland, USA

    Karel Pacak

  2. Department of Nuclear Medicine, Aix-Marseille University, Marseille, France

    David Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Taïeb, D., Pacak, K. (2017). Radionuclide Imaging of Chromaffin Cell Tumors. In: Pacak, K., Taïeb, D. (eds) Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-46038-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46038-3_14

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-46036-9

  • Online ISBN: 978-3-319-46038-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation